fulltext.pdf 181 KB
Iwata, Hiroji Okayama University Hospital
Systemic therapies for operable breast cancer patients have improved outcomes and have thus become standard treatments. Recently, new molecular target drugs and regimens are being developed based on the predicted sensitivity for specific breast cancer histological types. Systemic therapy is selected according to recurrence risk, with the treatment for low-risk patients being de-escalated, while high-risk patients receive aggressive systemic treatment with an adequate dose and duration. Neoadjuvant systemic therapy has a different aim. The efficacy of systemic therapies, based on the sensitivities to drugs, is supported by improvements in the rate of breast-conserving therapy. The response to neoadjuvant systemic therapy is the most important factor for predicting outcomes and selecting the optimal adjuvant therapy. Novel biological markers unique to individual patients allow appropriate targeted therapy, which can achieve optimal efficacy.
This is a pre-copyedited, author-produced version of an article accepted for publication in Japanese Journal of Clinical Oncology following peer review. The version of record TTadahiko Shien, Hiroji Iwata, Adjuvant and neoadjuvant therapy for breast cancer, Japanese Journal of Clinical Oncology, Volume 50, Issue 3, March 2020, Pages 225–229 is available online at: https://doi.org/10.1093/jjco/hyz213.
Japanese Journal of Clinical Oncology
Oxford University Press
Copyright © 2020 Oxford University Press
|Web of Science KeyUT|
Japan Agency for Medical Research and Development